A Phase 1b Study Of PF-05082566 In Combination With Mogamulizumab (KW-0761) In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Mogamulizumab (Primary) ; Utomilumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 24 Jul 2017 Planned End Date changed from 10 Aug 2017 to 1 Jan 2018.
- 24 Jul 2017 Planned primary completion date changed from 10 Aug 2017 to 1 Jan 2018.
- 09 Jun 2017 Status changed from suspended to recruiting.